Schacter Named Clinical Trials Director at Yale

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been named associate director for clinical trials for the Yale Cancer Center. In that role, he will oversee the clinical research projects on experimental cancer treatment taking place at the Center. Dr. Schacter comes to Yale from Bristol-Myers Squibb, where he was a director of the clinical cancer research program.

NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been namedassociate director for clinical trials for the Yale Cancer Center.In that role, he will oversee the clinical research projects onexperimental cancer treatment taking place at the Center. Dr.Schacter comes to Yale from Bristol-Myers Squibb, where he wasa director of the clinical cancer research program.

His top priority in his new position will be to further developmentof the Center's new clinical research program. "We have mostof the people in place," he said, referring to the Center'scorps of research scientists and physicians. "And we havepromising experimental treatment programs underway. That combinationmakes this a place people look to for progressive cancer therapy."

Dr. Schacter will also be instrumental in building a network forcommunity-based clinical research. The effort will involve extendingresearch projects to community hospitals throughout Connecticutas well as physicians' offices.

Recent Videos
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Related Content